Alaunos Therapeutics, Inc.
TCRT
$1.56
-$0.01-0.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 3.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 3.00K | -- | -- |
| Cost of Revenue | 388.00K | 427.00K | 361.00K | 469.00K | 185.00K |
| Gross Profit | -388.00K | -427.00K | -358.00K | -469.00K | -185.00K |
| SG&A Expenses | 564.00K | 585.00K | 549.00K | 718.00K | 854.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 952.00K | 1.01M | 910.00K | 1.19M | 1.04M |
| Operating Income | -952.00K | -1.01M | -907.00K | -1.19M | -1.04M |
| Income Before Tax | -952.00K | -1.01M | -893.00K | -1.16M | -1.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -952.00K | -1.01M | -893.00K | -1.16M | -1.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -952.00K | -1.01M | -893.00K | -1.16M | -1.05M |
| EBIT | -952.00K | -1.01M | -907.00K | -1.19M | -1.04M |
| EBITDA | -943.00K | -1.00M | -905.30K | -1.19M | -1.04M |
| EPS Basic | -0.39 | -0.52 | -0.43 | -0.53 | -0.63 |
| Normalized Basic EPS | -0.24 | -0.32 | -0.24 | -0.33 | -0.39 |
| EPS Diluted | -0.39 | -0.52 | -0.43 | -0.53 | -0.63 |
| Normalized Diluted EPS | -0.24 | -0.32 | -0.24 | -0.33 | -0.39 |
| Average Basic Shares Outstanding | 2.43M | 1.95M | 2.33M | 2.18M | 1.68M |
| Average Diluted Shares Outstanding | 2.43M | 1.95M | 2.33M | 2.18M | 1.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |